Protagenic Therapeutics (PTIX) Stock Analysis

Protagenic Therapeutics (PTIX) is a publicly traded company in the HEALTHCARE sector. It trades at $0.50. This page summarizes the public market data, fundamentals, and frequently asked questions for PTIX, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $0.50

About Protagenic Therapeutics

Protagenic Therapeutics, Inc. (PTIX) is a preclinical biopharmaceutical firm headquartered in New York, specializing in the development of innovative therapies aimed at treating stress-related mood and neuropsychiatric disorders. The company utilizes advanced research methodologies and cutting-edge technologies to identify and address significant unmet medical needs within this vital sector. With a strong commitment to enhancing patient mental health outcomes, Protagenic Therapeutics is posit...

GNG Research Analysis

GNG Research scores Protagenic Therapeutics (PTIX) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for PTIX.

Frequently Asked Questions

Does PTIX pay dividends?

Protagenic Therapeutics (PTIX) does not currently pay a regular dividend.